See more : Medacta Group SA (MEDGF) Income Statement Analysis – Financial Results
Complete financial analysis of ARYx Therapeutics, Inc. (ARYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ARYx Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Guangxi Liugong Machinery Co., Ltd. (000528.SZ) Income Statement Analysis – Financial Results
- Gladstone Acquisition Corporation (GLEEU) Income Statement Analysis – Financial Results
- Riddhi Corporate Services Limited (RIDDHICORP.BO) Income Statement Analysis – Financial Results
- Revelstone Capital Acquisition Corp. (RCACU) Income Statement Analysis – Financial Results
- Airtech Japan, Ltd. (6291.T) Income Statement Analysis – Financial Results
ARYx Therapeutics, Inc. (ARYX)
About ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.
| Metric | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 19.72M | 4.16M | 4.74M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 232.00K | 262.00K | 2.12M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 19.49M | 3.90M | 2.62M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 98.82% | 93.70% | 55.35% | 0.00% | 0.00% | 0.00% |
| Research & Development | 21.04M | 40.15M | 24.99M | 23.97M | 22.50M | 0.00 | 10.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.20M | 9.76M | 7.70M | 6.94M | 5.67M | 0.00 | 3.38M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -20.83M | 0.00 |
| Operating Expenses | 31.24M | 49.91M | 32.70M | 30.91M | 28.17M | -20.83M | 14.06M |
| Cost & Expenses | 31.24M | 50.14M | 32.96M | 33.03M | 28.17M | -20.83M | 14.06M |
| Interest Income | 78.00K | 1.13M | 2.59M | 2.29M | 876.00K | 0.00 | 0.00 |
| Interest Expense | 2.01M | 1.93M | 1.35M | 1.32M | 671.00K | 0.00 | 58.00K |
| Depreciation & Amortization | 1.08M | 1.46M | 1.24M | 920.00K | 982.00K | 0.00 | 0.00 |
| EBITDA | -30.06M | -29.32M | -27.56M | -27.37M | -26.73M | -20.83M | -14.06M |
| EBITDA Ratio | 0.00% | -146.80% | -662.87% | -577.51% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.24M | -30.42M | -28.80M | -28.29M | -28.17M | -20.83M | -14.06M |
| Operating Income Ratio | 0.00% | -154.21% | -692.64% | -596.92% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.93M | -801.00K | 1.24M | 970.00K | 205.00K | 0.00 | 0.00 |
| Income Before Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 849.00K | 801.00K | -1.24M | -960.00K | -205.00K | 20.83M | 13.97M |
| Net Income | -33.17M | -31.22M | -27.56M | -27.33M | -27.96M | -20.83M | -13.97M |
| Net Income Ratio | 0.00% | -158.27% | -662.84% | -576.66% | 0.00% | 0.00% | 0.00% |
| EPS | -1.21 | -1.65 | -8.24 | -26.84 | -30.73 | -24.27 | -16.67 |
| EPS Diluted | -1.21 | -1.65 | -8.24 | -26.84 | -30.73 | -24.27 | -16.67 |
| Weighted Avg Shares Out | 27.44M | 18.96M | 3.35M | 1.02M | 910.00K | 858.00K | 838.00K |
| Weighted Avg Shares Out (Dil) | 27.44M | 18.96M | 3.35M | 1.02M | 910.00K | 858.00K | 838.00K |
Source: https://incomestatements.info
Category: Stock Reports